1-12 of 12
François Romagné
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Holbrook E. Kohrt, Ariane Thielens, Aurelien Marabelle, Idit Sagiv-Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, Eric Vivier, François Romagné, Ronald Levy, Mathieu Bléry, Pascale André
Journal: Blood
Blood (2014) 123 (5): 678–686.
https://doi.org/10.1182/blood-2013-08-519199
Published: 2014
Includes: Supplemental data
Journal Articles

Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies

Holbrook E Kohrt, MD, PhD, Ariane Thielens, Aurelien Marabelle, MD, MSc, Idit Sagiv Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra K Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, PhD, Eric Vivier, PhD, Francois Romagne, PhD, Ronald Levy, MD, Pascale Andre, PhD, Mathieu Blery, PhD
Journal: Blood
Blood (2013) 122 (21): 4417.
https://doi.org/10.1182/blood.V122.21.4417.4417
Published: 2013
Journal Articles

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

Clinical Trials & Observations
Norbert Vey, Jean-Henri Bourhis, Nicolas Boissel, Dominique Bordessoule, Thomas Prebet, Aude Charbonnier, Anne Etienne, Pascale Andre, François Romagne, Don Benson, Herve Dombret, Daniel Olive
Journal: Blood
Blood (2012) 120 (22): 4317–4323.
https://doi.org/10.1182/blood-2012-06-437558
Published: 2012
Includes: Supplemental data
Journal Articles

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Brief Report
Don M. Benson, Jr, Courtney E. Bakan, Shuhong Zhang, Shauna M. Collins, Jing Liang, Shivani Srivastava, Craig C. Hofmeister, Yvonne Efebera, Pascale Andre, Francois Romagne, Mathieu Bléry, Cécile Bonnafous, Jianying Zhang, David Clever, Michael A. Caligiuri, Sherif S. Farag
Journal: Blood
Blood (2011) 118 (24): 6387–6391.
https://doi.org/10.1182/blood-2011-06-360255
Published: 2011
Includes: Supplemental data
Journal Articles

Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML)

Jerome Rey, MD, Nicolas Anfossi, PhD, Pascale Andre, PhD, Jean-Marie Boher, Florence Orlanducci, Violette Breso, Valentine Perri, Thomas Prebet, MD, PhD, Aude Charbonnier, MD, PhD, Eloïse Perrot, Francois Romagne, PhD, Norbert Vey, MD, Daniel Olive, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2189.
https://doi.org/10.1182/blood.V118.21.2189.2189
Published: 2011
Journal Articles

Long Lasting Alteration of Natural Killer Cells Post-Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML).

Daniel Olive, MD, PhD, Nicolas Anfossi, Pascale Andre, PhD, Jerome Rey, Florence Orlanducci, Violette Breso, Valentine Peri, Thomas Prébet, MD, Aude Charbonnier, MD, PhD, Eloise Perrot, Francois Romagne, PhD, Norbert Vey
Journal: Blood
Blood (2009) 114 (22): 1653.
https://doi.org/10.1182/blood.V114.22.1653.1653
Published: 2009
Journal Articles

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Don Benson, MD, PhD, Courtney E Bakan, Shuhong Zhang, PhD, Lana Alghothani, Jing Liang, Craig Hofmeister, MD, Shivani Srivastava, MD, Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, MD, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD
Journal: Blood
Blood (2009) 114 (22): 3870.
https://doi.org/10.1182/blood.V114.22.3870.3870
Published: 2009
Journal Articles

A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH2101) in Elderly Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological Effects of a Single Dose Followed by Repeated Dosing.

Norbert Vey, Jean-Henri Bourhis, MD, PhD, Herve Dombret, MD, PhD, Dominique Bordessoule, Thomas Prébet, MD, Aude Charbonnier, Stephane de Botton, Nicolas Boissel, MD, PhD, Christine d'Arnoux, MD, Francois Romagne, PhD, Pascale Andre, PhD, Jerome Tiollier, Patrick Squiban, Didier Blaise, Daniel Olive, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 632.
https://doi.org/10.1182/blood.V114.22.632.632
Published: 2009
Journal Articles

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.

Don Benson, MD, PhD, Courtney E Bakan, Lana Alghothani, Craig C. Hofmeister, MD, Yvonne A Efebera, M.D., Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Steven M Devine, MD
Journal: Blood
Blood (2009) 114 (22): 4641.
https://doi.org/10.1182/blood.V114.22.4641.4641
Published: 2009
Journal Articles

IPH1101, the First Specific γδ T Cell Agonist, Shows Potent Immuno-Biological Efficacy in Low Grade Follicular Lymphoma Patients When Combined with Rituximab: Results From a Phase II Study.

Claire Lucas, Sophie Ingoure, Elodie Soule, Bruna Faria, Fabien Audibert, Mathieu Blery, Lucile Beautier, Francois Romagne, PhD, Sylvie de Micheaux, MD, Helene Sicard, PhD
Journal: Blood
Blood (2009) 114 (22): 583.
https://doi.org/10.1182/blood.V114.22.583.583
Published: 2009
Journal Articles

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Francois Romagné, Pascale André, Pieter Spee, Stefan Zahn, Nicolas Anfossi, Laurent Gauthier, Marusca Capanni, Loredana Ruggeri, Don M. Benson, Jr, Bradley W. Blaser, Mariella Della Chiesa, Alessandro Moretta, Eric Vivier, Michael A. Caligiuri, Andrea Velardi, Nicolai Wagtmann
Journal: Blood
Blood (2009) 114 (13): 2667–2677.
https://doi.org/10.1182/blood-2009-02-206532
Published: 2009
Includes: Supplemental data
Journal Articles

Anti-KIR (1-7F9): A Fully Human Monoclonal Antibody (mAb) That Blocks KIR2DL1, −2 and −3, Promoting Natural Killer (NK) Cell-Mediated Lysis of Tumor Cells In Vitro and In Vivo.

Nicolai Wagtmann, PhD, Pascale Andre, PhD, Stefan Zahn, PhD, Pieter Spee, PhD, Nicolas Anfossi, PhD, Laurent Gauthier, PhD, Bradley W. Blaser, PhD, Michael A. Caligiuri, MD, Marusca Capanni, Loredana Ruggeri, PhD, Andrea Velardi, MD, Francois Romagne, PhD
Journal: Blood
Blood (2007) 110 (11): 582.
https://doi.org/10.1182/blood.V110.11.582.582
Published: 2007